clinical-trial

Clinical trials in melanoma

Clinical trials may be worth discussing at diagnosis, after recurrence, after immunotherapy failure, or when a mutation-specific option is unclear.

Plain-English summary

Trial listings can show studies that mention a cancer, mutation, drug, or treatment history, but a listing match does not mean a study fits.

What the sources say

• ClinicalTrials.gov and NCI trial data are listing sources, not decisions about whether a trial fits.
• NCT06008106 is a current example of an NRAS-mutant melanoma trial record that mentions prior immunotherapy and compares tunlametinib with chemotherapy.
• Trial listing text can be incomplete or delayed, so the public UI must say 'may be relevant' rather than confirming that a study fits.

When this commonly comes up

• The mutation result is uncommon or treatment options are unclear.
• Disease recurs or progresses after a prior treatment.
• The family wants to understand options before starting the next line.

What this does not mean

• A trial listing match does not mean the trial fits.
• A trial listing does not mean the site is actively enrolling today.
• A trial option does not replace an oncology-team discussion.

Important cautions

• The trial team must confirm whether the trial fits.
• Registry status can lag real recruitment status.
• Starting a treatment can affect whether later trials fit, so timing questions matter.

Questions to ask

• Should we search trials before starting the next treatment?
• What search terms should we use: cancer subtype, mutation, prior therapy, or drug?
• Would this treatment make a later trial no longer fit?
• Who can contact the trial team?